TICKERNERD
Menu
BLLNBLLNHealthcare · Diagnostics & Research

BLLN Stock Forecast: BillionToOne, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$137
−0.92% on the day

The 8 Wall Street analysts covering BillionToOne, Inc. hold a median 12-month price target of $120 — -12.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap
$6.4B
Ticker Nerd rank
12 / 100
Median analyst target
$120
Analysts covering
8
Total return, dividends reinvested
1W
+7.3%
1M
+14.1%
YTD
+67.8%
From high
−1.6%
From low
+114.5%
$64
$140
Range since 6 Nov 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

BLLN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BillionToOne, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
12 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
94
Growth
37
Momentum
31
Value
29
Size
21
Quality
15
Issuance
13
Accruals
8
Volatility
4

Revisions (94): Analysts have, on balance, been raising their forecasts.

Volatility (4): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own BillionToOne, Inc. — and when they’d sell — is the membership.

Wall Street

BLLN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BLLN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 6 Nov 2025Adjusted close, US dollars
$60$80$100$120$140Jan 26Apr 26Jul 26BLLNHigh $145Median $120Low $90

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
6 Buy2 Hold0 Sell
Low $90Median $120High $145

The green dot is the last close — the median target sits −12.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 June 2026GuggenheimInitiatesBuy$120 → $125
13 May 2026GuggenheimMaintainsBuy—
7 May 2026BTIGMaintainsBuy—
7 May 2026JP MorganMaintainsOverweight—
30 Mar 2026GuggenheimMaintainsBuy—
5 Mar 2026BTIGMaintainsBuy—
5 Mar 2026GuggenheimReiteratesBuy—
5 Mar 2026Wells FargoMaintainsEqual-Weight—
10 Dec 2025BTIGReiteratesBuy—
10 Dec 2025JP MorganMaintainsOverweight—
1 Dec 2025BTIGInitiatesBuy—
1 Dec 2025JefferiesInitiatesHold—
1 Dec 2025JP MorganInitiatesOverweight—
1 Dec 2025Piper SandlerInitiatesOverweight—
1 Dec 2025StifelInitiatesBuy—
1 Dec 2025Wells FargoInitiatesEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

BLLN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+128.9%
Analysts raising
1
Analysts cutting
0
Fundamentals

BillionToOne, Inc. (BLLN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
256.7×

Cheaper than 3% of US stocks

Price / sales
18.0×

Cheaper than 10% of US stocks

Price / book
12.6×

Cheaper than 8% of US stocks

EV / EBITDA
139.0×

Cheaper than 2% of US stocks

Growth & margins
Revenue growth (YoY)
83.8%

Higher than 92% of US stocks

Earnings growth (YoY)
140.5%

Higher than 89% of US stocks

Gross margin
73.0%

Higher than 86% of US stocks

Operating margin
16.5%

Higher than 76% of US stocks

Net margin
7.0%

Higher than 64% of US stocks

Returns & dividend
Return on equity
8.7%

Higher than 61% of US stocks

Return on assets
4.5%

Higher than 74% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BLLN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
BLLNBillionToOne, Inc.$6.4B
12
TWSTTwist Bioscience Corp.$5.6B
58
SHCSotera Health Co.$5.1B
87
RDNTRadNet, Inc.$5.0B
42
QGENQiagen NV$8.6B
61
VCYTVeracyte, Inc.$3.7B
95
ADPTAdaptive Biotechnologies Corp.$3.6B
77
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BLLN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest BLLN news & analysis

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

Investors Business Daily · 3 Aug 2026neutral

The article notes that stocks including Eli Lilly, Twilio, and Hinge Health are approaching their earnings reports, and advises investors to watch key chart lines as these reports near. The piece focuses on technical levels ahead of upcoming earnings releases.

Why it matters — As a broader market/earnings-focused piece referencing other companies, it offers no direct information about BillionToOne but reflects the kind of earnings-season chart scrutiny investors may apply to BLLN as well.

FAQ

Frequently asked questions about BLLN stock

What is the BLLN stock price forecast for 2026-2027?

The 8 Wall Street analysts covering BillionToOne, Inc. have a median 12-month price target of $120, with estimates ranging from $90 to $145. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BLLN stock a buy right now?

Of the 8 analysts covering BillionToOne, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BillionToOne, Inc. 12 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BLLN?

As at 1 Aug 2026, BillionToOne, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (94 of 100).

Will BLLN stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies -12.6% from the last close, and Ticker Nerd's factor model ranks BillionToOne, Inc. 12 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BLLN stock forecast for 2030?

No analyst covering BillionToOne, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $90 to $145 over the next 12 months.

What does BillionToOne, Inc. do?

BillionToOne, Inc. is a precision diagnostics company specializing in the development of advanced molecular diagnostic tests for healthcare applications.

What is the latest news on BLLN?

The most recent item we track (Investors Business Daily, 3 Aug 2026): "Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test". The article notes that stocks including Eli Lilly, Twilio, and Hinge Health are approaching their earnings reports, and advises investors to watch key chart lines as these reports near. The piece focuses on technical levels ahead of upcoming earnings releases.

Company

About BillionToOne, Inc.

BillionToOne, Inc. is a precision diagnostics company specializing in the development of advanced molecular diagnostic tests for healthcare applications. The company’s core innovation is its proprietary single-molecule next-generation sequencing (smNGS) platform, which enables highly sensitive and accurate detection and quantification of DNA molecules at the single-molecule level. This technological breakthrough underpins BillionToOne’s flagship product lines, including UNITY Complete, a non-invasive prenatal screening test that assesses fetal risk for chromosomal aneuploidies, recessive conditions such as sickle cell disease and cystic fibrosis, and fetal antigens, all from a single maternal blood draw. Additionally, the company’s Northstar Select and Northstar Response tests are designed for oncology, offering sensitive liquid biopsy solutions that guide therapy selection and provide longitudinal monitoring of cancer burden. BillionToOne’s molecular counting technologies are intended to address significant unmet needs in both the prenatal and oncology sectors, enabling earlier, safer, and more comprehensive disease detection. With a mission to improve healthcare accessibility and patient outcomes, BillionToOne plays a transformative role in the diagnostics and research segment of the healthcare market, supporting the shift toward personalized and non-invasive medicine.

CEO Dr. Oguzhan Atay Ph.D. · 713 employees · United States · https://www.billiontoone.com